fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-02-05
Biotech partner: DxS, subsidiary of Qiagen (The Netherlands)
Pharma Partner: Pfizer (USA)
Type of agreement: * licensing
* development
Compound: companion diagnostic test kit for the immunotherapy vaccine PF-04948568 (CDX-110). PF-04948568 is a 14 amino acid peptide chemically conjugated to Keyhole Limpet Hemocyanin (KLH). It is targeting the tumor specific epidermal growth factor receptor (EGFR) mutant EGFRvIII. On April 16, 2008, Pfizer Vaccines LLC. has been granted an exclusive worldwide license to the product. A phase II study is ongoing in patients with glioblastoma multiforme (ACT III) (See clintrials.gov).
Disease area: glioblastoma multiforme
Nature of the agreement: Pfizer and DxS -(have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).
The assay is designed to identify patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment. The diagnostic will be a real-time PCR assay used to detect EGFRvIII RNA in tumor tissue.
This companion diagnostic will be developed and manufactured at Qiagen’s Center of Excellence for Companion Diagnostics in Manchester, UK.
Financial terms of the agreement: Financial terms of agreement were not disclosed.


Go back to previous page